Neurologic toxicities of cancer therapies.

Current Neurology and Neuroscience Reports
Robert Cavaliere, David Schiff

Abstract

Neurologic dysfunction is a well-recognized adverse effect of cancer therapeutics. The most common manifestations include peripheral neuropathy and encephalopathy. Often, symptoms resolve or improve upon removal of the offending agent; therefore, it is essential that clinicians recognize the symptoms and signs of injury. Occasionally, symptoms persist or develop after discontinuation of medication and may culminate in disability and diminished quality of life. As our understanding of neurotoxicity improves, medications with less potential for injury may be developed. In addition, potential antidotes to prevent or reverse injury may emerge. This review focuses on the clinical features, mechanisms, and possible therapeutics of the neurotoxicity of chemotherapy. In particular, oxaliplatin, thalidomide, methotrexate, ifosfamide, cytarabine, amifostine, acetyl-L-carnitine, methylene blue, cytokines, and neurotrophins are discussed.

References

Apr 2, 1999·The European Journal of Neuroscience·M J Courtney, E T Coffey
Oct 3, 1999·Experimental Neurology·G TrediciG Cavaletti
Jul 15, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C B BrezdenI F Tannock
Mar 10, 2001·Clinical Pharmacokinetics·T KerbuschJ H Beijnen
May 3, 2001·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M PenzW Scheithauer
May 10, 2001·Medical and Pediatric Oncology·H PeyriereD Hillaire-Buys
Jan 12, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tim A AhlesPeter M Silberfarb
Mar 29, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard H WilsonJean L Grem
Jun 25, 2002·Pediatric Hematology and Oncology·Richard A DrachtmanBarton A Kamen
Sep 12, 2002·Pharmacotherapy·Geri M GowanAlexander B Simonetta
Nov 26, 2002·The Journal of Investigative Dermatology·Sylvie Bastuji-GarinUNKNOWN Thalidomide Neuropathy Study Group
Nov 28, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ChiusoloS Sica
Mar 12, 2003·Neurology·F GianniniA Cerase
Mar 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tracy BatchelorRegina Priet
May 2, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Swan Swan LeongPeng Tiam Ang
Jul 11, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D LorussoUNKNOWN Multicenter Italian Trials in Ovarian Cancer invesitgators
Aug 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shinji KishiMary V Relling
Oct 23, 2003·Clinical Oncology : a Journal of the Royal College of Radiologists·A R TurnerD J Good
Oct 31, 2003·Oncology·P Nicolao, B Giometto
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nadine TchenIan F Tannock
Nov 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H MooreUNKNOWN Gynecologic Oncology Group
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Harry OpenshawGeorge Somlo
Feb 7, 2004·Acta Neurologica Scandinavica·G IsoardoD Cocito
Feb 10, 2004·Journal of Pediatric Hematology/oncology·Ashok B RajNorman Jaffe
Feb 21, 2004·The Journal of Otolaryngology·Abdulmohsen E HussainJanet Balderston
Apr 2, 2004·Anti-cancer Drugs·C RiegerX Schiel

❮ Previous
Next ❯

Citations

Mar 20, 2012·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Barbara K BennettDavid Goldstein
Jan 3, 2013·Psychiatry and Clinical Neurosciences·Mustafa GulecHalis Suleyman
Aug 24, 2010·Journal of Endodontics·Yehuda ZadikSharon Elad
Mar 24, 2009·Pediatric Neurology·Kouhei HamamotoKeigo Endo
Jul 7, 2007·Journal of the Neurological Sciences·Massimiliano FilostoAlessandro Padovani
Aug 6, 2011·Journal of Applied Toxicology : JAT·Haseeb Ahmad Khan, Abdullah Saleh Alhomida
Oct 12, 2010·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Manuela FantiniAlberto Ravaioli
Sep 7, 2012·Progress in Transplantation : Official Publication, North American Transplant Coordinators Organization ... [et Al.]·Laura Hanssen Textor, Jane Hedrick
Mar 23, 2007·Journal of Surgical Oncology·Julie Silver, R Samuel Mayer
Jul 16, 2014·Dalton Transactions : an International Journal of Inorganic Chemistry·Risikat Ajibola AdigunReuben H Simoyi
Feb 9, 2017·Journal of Neurochemistry·Noha F AbdelkaderRania M Abdelsalam
Dec 17, 2014·American Journal of Physiology. Gastrointestinal and Liver Physiology·Vanesa StojanovskaKulmira Nurgali
Nov 30, 2018·CNS & Neurological Disorders Drug Targets·David Calderón GuzmánGerardo Barragán Mejía

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.